From Precision Mechanism to R&D Breakthroughs: ADCs Leading a New Era in Cancer Therapy

In recent years, Antibody–Drug Conjugates (ADCs) have rapidly emerged in the field of oncology, serving as a crucial bridge between traditional chemotherapy and targeted therapy.

With their dual advantages of “precise targeting” and “potent cytotoxicity,” ADCs are widely regarded as one of the key technologies shaping the next generation of cancer treatment.

As global competition in innovative therapeutics intensifies, ADCs have demonstrated significant clinical potential and have become a major focus across the entire pharmaceutical value chain. In this context, multiple stakeholders—including pharmaceutical innovators, healthcare institutions, and professional pharmaceutical distribution companies—are working together to improve patient access to ADC therapies. As an important participant in pharmaceutical wholesale and supply chain services, DengYue Medicine is also actively engaged in supporting the development and distribution of innovative drugs.

How ADCs Achieve Precision Therapy

ADCs typically consist of three components: a monoclonal antibody, a linker, and a cytotoxic payload. Their mechanism of action involves several key steps.

First, the antibody specifically recognizes and binds to antigens expressed on the surface of tumor cells, enabling precise targeting of the disease site. The ADC–antigen complex is then internalized into the cell via endocytosis.

Within the lysosomal environment, the linker is cleaved or degraded, releasing the highly potent cytotoxic agent. These payloads subsequently exert their effects by disrupting microtubules or inducing DNA damage, ultimately leading to tumor cell death. In some cases, a “bystander effect” may also occur, allowing the drug to affect neighboring tumor cells and further enhance therapeutic efficacy.

This mechanism allows ADCs to improve treatment outcomes while minimizing damage to normal tissues. Compared with conventional chemotherapy, ADCs offer superior selectivity and safety, making them an important pathway toward “precision chemotherapy.”

Rapid Development of ADCs in China

Amid the global wave of ADC innovation, China is transitioning from a follower to an emerging innovator, achieving a series of significant milestones.

On one hand, several ADC drugs have been commercialized or have entered late-stage clinical development. For example, Disitamab vedotin marks a key milestone in the commercialization of domestically developed ADCs in China, demonstrating promising efficacy in indications such as gastric cancer and urothelial carcinoma.

On the other hand, research targets have expanded beyond HER2 to include a broader range of emerging targets such as TROP2, CLDN18.2, HER3, and B7-H3, reflecting deeper exploration of tumor biology. Meanwhile, multiple ADC candidates have advanced into Phase III clinical trials, highlighting the growing competitiveness of Chinese pharmaceutical companies on the global stage.

At the technological level, Chinese companies are actively advancing next-generation ADC platforms, including more stable or conditionally cleavable linkers, more effective and safer payloads, and innovative designs such as bispecific ADCs. In addition, the combination of ADCs with immunotherapies is becoming an important research direction, with the potential to further enhance clinical outcomes.

As innovation accelerates, improving the efficient delivery of these therapies to clinical practice has become a critical issue. Pharmaceutical wholesale companies, represented by DengYue, play a vital role in drug supply, channel integration, and compliant distribution, helping to ensure that innovative therapies such as ADCs reach patients more effectively.

Future Trends: From Single Modality to Multidimensional Innovation

Looking ahead, ADC development is expected to evolve along multiple dimensions.

In terms of indications, ADCs are likely to expand from late-stage cancers to earlier lines of therapy, including adjuvant settings. In therapeutic strategies, combination regimens—such as ADCs with immune checkpoint inhibitors—will become increasingly important. Furthermore, the application of ADCs is extending beyond oncology, with emerging research exploring their potential in non-oncological diseases such as autoimmune disorders.

At the same time, with technological advancements and a more mature industry ecosystem, ADC development is moving toward platform-based approaches. By standardizing the combination of antibodies, linkers, and payloads, companies can accelerate the development of multiple products, thereby improving R&D efficiency and market competitiveness.

In this process, a well-developed pharmaceutical distribution system is equally essential, as it directly impacts drug accessibility and the efficiency of market translation.

Conclusion: ADCs Reshaping the Landscape of Cancer Treatment

Overall, ADCs integrate precise targeting with potent cytotoxic effects through their unique mechanism of action, reshaping the paradigm of cancer therapy. Represented by innovations such as Disitamab vedotin, China has already established a strong competitive position in this field.

Looking forward, with continuous discovery of new targets, advancement of technology platforms, and deepening global collaboration, ADCs are expected to play an increasingly important role across a wider range of diseases.

Meanwhile, with the support of professional pharmaceutical wholesalers such as HongKong DengYue Medicine, the pathway from drug development to clinical application will become more efficient, further advancing the realization of precision medicine.